1. Scrip
  2. >>Focus On Asia
  3. >>China

China Investment Roundup: Strategic Overseas Moves Target Product Acquisitions

 
• By Ying Huang

R&D-based big pharma groups in China with sufficient cash flow are increasing their strategic investments in overseas companies and products with an eye on entry to the global market, while start-ups continue to actively raise new funds from venture capitalists.

China globe
Big pharma increasing strategic investement oversea

A number of Chinese big pharma firms are striving to find new ways to break free of bottlenecks in new drug discovery and development, including through strategic investments in foreign biophama companies, given that the Chinese companies may depend heavily on single products to generate most of their revenues from the domestic market.

Shanghai-listed Tasly Pharmaceutical Co. Ltd., one of China’s largest companies specializing in developing modern traditional Chinese medicines (TCM), made a strategic investment of €20m ($22.4m) for a 12

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.